A meta-analysis published at the same time as the EMPA-KIDNEY trial includedpatient-level data from all the major placebo-controlled trials conducted withSGLT2 inhibitors up to and including EMPA-KIDNEY.48 The key findings from themeta-analysis of these 13 trials (total N = 90 413) were that relative toplacebo, treatment with an SGLT2 inhibitor reduced the risk of kidney diseaseprogression by 37% (relative risk [RR] 0.63, 95% confidence interval [CI]0.58-0.69) with similar RRs in patients with and without diabetes. The gene discussed is SLC5A2; the disease is diabetes mellitus.